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Abstract
Introduction While there is a substantial body of lit-
erature on the comparative healthcare costs of biologics
used to treat rheumatoid arthritis (RA), nearly all of these
investigations have been exclusively focused on anti-tumor
necrosis factor-a (anti-TNF) agents in the setting of first-
line biologic treatment. This study compared healthcare
costs between RA patients treated with infused biologics
after previously using at least one other biologic agent.
Methods Using a large US administrative claims dataset,
adult RA patients initiating an infused biologic (abatacept,
infliximab, tocilizumab) between January 1, 2010 and
January 1, 2012 (initiation = index) were identified.
Rituximab was excluded because of unique dosing inter-
vals, which make it difficult to determine treatment dis-
continuation using a claims database. Patients were
required to have used one or more other biologic (infused
or injected) at any time before index. Patients could con-
tribute multiple observations to the dataset; one for each
infused biologic they initiated between January 1, 2010 and
January 1, 2012. A 6-month period before index was used
to measure patient characteristics. A variable-length fol-
low-up period after index was used to measure per-patient
per-month (PPPM) healthcare costs, including biologic
costs, RA-related healthcare costs, and all-cause healthcare
costs. Generalized estimating equations models compared
healthcare costs between the biologic agents, adjusting for
patients’ demographics and clinical characteristics.
Results The sample comprised 3,771 infused
biologic initiations (abatacept = 1,759; infliximab = 922;
tocilizumab = 1,090); the mean age of participants was 55
years, 82 % were female, and the median follow-up ranged
from 251 to 280 days. Compared with other patients,
patients treated with tocilizumab had significantly lower
(all P \ 0.05) PPPM biologic costs (abatacept = $2,597,
infliximab = $3,141, tocilizumab = $1,894), RA-related
healthcare costs (abatacept = $2,929, infliximab =
$3,598, tocilizumab = $2,236), and all-cause healthcare
costs (abatacept = $3,735, infliximab = $4,600, tocilizum-
ab = $3,042).
Conclusions Among RA patients treated with infused
biologics after previously using at least one other biologic,
patients treated with tocilizumab had the lowest real-world
healthcare costs, largely driven by lower costs directly
related to biologic treatment. Such biologic-related cost
differences may be driven by variations in real-world
treatment patterns (e.g., dose, escalation, treatment
frequency).
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Key Points
While there is a substantial body of literature on the
comparative healthcare costs of biologics used to
treat rheumatoid arthritis (RA), nearly all of these
investigations have been exclusively focused on anti-
tumor necrosis factor-a (anti-TNF) agents in the
setting of first-line biologic treatment.
This study compared healthcare costs between RA
patients treated with infused biologics after
previously using at least one other biologic agent.
Using a large US administrative claims dataset, adult
RA patients initiating an infused biologic (abatacept,
infliximab, tocilizumab) between January 1, 2010
and January 1, 2012 (initiation = index) were
identified.
A variable-length follow-up period after index was
used to measure per-patient per-month healthcare
costs, including biologic costs, RA-related
healthcare costs, and all-cause healthcare costs.
Among RA patients treated with infused biologics
after previously using at least one other biologic,
patients treated with tocilizumab had the lowest real-
world healthcare costs.
Introduction
In the treatment of rheumatoid arthritis (RA), biologic
agents are recommended for patients who have experi-
enced an inadequate response to conventional disease
modifying anti-rheumatic drugs [1]. Among the biologic
agents currently approved for treatment of RA, seven may
be self-administered through subcutaneous injection
(abatacept, adalimumab, anakinra, certolizumab, etaner-
cept, golimumab, and tocilizumab) and five have to be
administered through intravenous infusion by a healthcare
provider (abatacept, golimumab, infliximab, tocilizumab,
and rituximab). The choice between self-administered and
healthcare provider-administered agents can depend on a
number of factors, including patient and provider prefer-
ences, reimbursement, and insurance coverage policies
[2–4].
The American College of Rheumatology recommends
the use of anti-tumor necrosis factor-a (anti-TNF) therapies
as the first-line option when initiating a patient with RA on
biologic therapy [1]. Thus, most infused biologics, three of
which are not anti-TNF therapies, are usually used in
patients who have previously used at least one other
biologic agent. Among such patients for whom a biologic
with an infused route of administration has been chosen,
the available therapies differ widely with respect to
mechanism of action, frequency of administration, and
variation in dosing options [5–8].
US payers are increasingly relying on real-world, com-
parative healthcare utilization and cost data when making
decisions related to the coverage of therapies [9, 10]. While
there is a substantial body of literature on the comparative
healthcare costs of biologics used to treat RA, nearly all of
these investigations have been exclusively focused on anti-
TNF agents in the setting of first-line biologic treatment
[11–19]. Though two prior studies have examined health-
care costs among patients treated with the infused biologics
abatacept, infliximab, and rituximab, both were intended to
be purely descriptive and made no attempts to adjust for
inherent differences in patient characteristics that may
drive differences in healthcare costs [20, 21]. Furthermore,
to date, no prior studies have examined the costs of RA
patients treated with tocilizumab. Thus, the objective of
this retrospective, observational cohort study was to com-
pare healthcare costs between RA patients treated with
infused biologics after previously using at least one other
biologic agent. This study focuses specifically on infused
biologics to provide specific, comparative information on
these agents to inform treatment choice when circum-
stances such as insurance coverage or patient/provider




This was a retrospective, observational cohort study based
on US administrative claims data extracted from the Tru-
ven Health MarketScan Commercial Claims and
Encounters (Commercial) and Medicare Supplemental and
Coordination of Benefits (Medicare Supplemental)
databases. These databases comprise enrollment informa-
tion, demographic information, and inpatient medical,
outpatient medical, and outpatient pharmacy claims data
collected from over 300 large self-insured US employers
and over 25 US health plans. The Commercial database
includes information on individuals who are under the age
of 65 and are the primary insured or a spouse or dependent
thereof. The Medicare Supplemental database includes
information for individuals who are Medicare eligible and
have a supplemental insurance paid for by their current or
former employer. The study databases contained data for
over 40 million unique individuals in 2011. These
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databases have been used in multiple studies related to RA
[22].
The study databases satisfy the conditions set forth in
Sections 164.514 (a)–(b)1ii of the Health Insurance
Portability and Accountability Act of 1996 privacy rule
regarding the determination and documentation of statis-
tically de-identified data. Because this study used only
de-identified patient records and does not involve the col-
lection, use, or transmittal of individually identifiable data,
Institutional Review Board approval to conduct this study
was not necessary.
As described in greater detail below, study variables
were measured from the database using enrollment records,
International Classification of Diseases, 9th Revision,
Clinical Modification (ICD-9-CM) codes, Current Proce-
dural Technology, 4th edition (CPT-4) codes, Healthcare
Common Procedure Coding System (HCPCS) codes, and
National Drug Codes (NDCs), as appropriate [23].
Patient Selection Criteria
Patients were included in the analysis if they met all of the
following selection criteria: initiated an infused biologic
agent (abatacept, infliximab, or tocilizumab) between
January 1, 2010 and January 1, 2012 (the dates of ini-
tiation for biologic agents used during this period were
designated as the index dates); used at least one other
biologic (either subcutaneous or an intravenous agent) at
any time prior to the index date; had at least one inpatient
or non-diagnostic outpatient medical claim (i.e., excluding
medical claims such as radiology and venipuncture, which
may represent services that are used to diagnose or rule
out the presence of a condition) with a diagnosis of RA
(ICD-9-CM code 714.0x) between January 1, 2009 and
March 31, 2012; were aged 18 years or older on the index
date; were continuously enrolled, according to insurance
enrollment records, for at least 6 months pre-index (des-
ignated as the baseline period) and at least 3 months post-
index; and had no medical claims with diagnosis codes for
any non-RA indication of biologic agents (ankylosing
spondylitis, chronic lymphocytic leukemia, Crohn’s dis-
ease, juvenile idiopathic arthritis, polyarteritis nodosa,
non-Hodgkin’s lymphoma, plaque psoriasis, psoriatic
arthritis, ulcerative colitis, or Wegener’s granulomatosis)
within the baseline period. Patients initiating treatments
with induction doses were not necessarily required to
complete the induction phase of treatment in order to be
retained in the analysis.
An episode-based study design was used wherein pa-
tients were allowed to contribute multiple observations to
the dataset, one for each infused biologic they initiated
sequentially during the study period. Thus, patients were
followed forward in time after their first qualifying infused
biologic initiation to capture all subsequent episodes of
infused biologic use. Episodes of infused biologic use
began with initiation of a new infused biologic, with fol-
low-up extending until the first occurrence of a 90-day gap
in treatment with the initiated biologic, switch to a different
biologic, insurance disenrollment, or the end of the study
period (March 31, 2012).
Rituximab was not included in the analyses because of
unique dosing intervals, which make it difficult to deter-
mine treatment discontinuation using a claims database.
Specifically, the recommended frequency of rituximab
re-infusions was initially based on clinical evaluation but
later updated to be every 24 weeks or based on clinical
evaluation, but not sooner than every 16 weeks. Because
the magnitude of estimated healthcare costs incurred while
a patient is being treated with a biologic is highly sensitive
to the time period over which a patient is determined to be
‘on treatment,’ censoring follow-up at a 90-day gap may
artificially inflate the cost of care for RA patients who are
being treated with rituximab based on clinical evaluation.
Healthcare Cost Outcomes
The study outcomes were per-patient per-month (PPPM)
healthcare costs measured during the follow-up. PPPM is
calculated by dividing the total costs incurred during the
episode by the number of days in the episode and then
multiplying the resultant per-day costs by 30 to normalize
costs to a 30-day (monthly) unit. The use of PPPM costs
therefore accounts for the fact that patient follow-up is not
necessarily equal for all patients. Healthcare costs were
classified into (1) biologic costs (biologic drug ? admin-
istration), (2) RA-related healthcare costs, which included
costs for drugs used in symptomatic treatment
[biologic drug ? administration ? non-biologic RA drugs
(methotrexate, hydroxychloroquine, leflunomide, minocy-
cline, sulfasalazine, cyclosporine, azathioprine, gold sodi-
um thiomalate, non-steroidal anti-inflammatory drugs,
corticosteroids, other analgesics) ? medical claims coded
with ICD-9-CM diagnosis codes for RA], and (3) all-cause
healthcare costs (all pharmacy and medical claims).
Healthcare costs were measured from the payment field on
adjudicated medical and pharmacy insurance claims within
the database. These costs include the gross covered pay-
ments for all healthcare services or products (i.e., the
amount eligible for payment after applying pricing guide-
lines such as fee schedules and discounts, but including
deductibles, copayments, and coordination of benefits).
Healthcare costs were expressed in 2011 constant US
dollars, adjusted using the Medical Care component of the
Consumer Price Index [24].
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Covariates
The study covariates included patient demographics and
clinical characteristics thought to potentially confound the
relationship between the healthcare costs outcomes and
biologic agent. Patient demographics were measured at
index and are listed in Table 1. Patient clinical charac-
teristics were measured throughout the baseline period
and are listed in Table 2 [25, 26]. The clinical charac-
teristics included an administrative claims-based RA
severity score [27]. This score has been shown to have
moderate correlations with a previously validated records-
based index of severity that had established construct and
convergent validity with the Disease Activity Score in 28
Joints (DAS28). The Claims-based Index for Rheumatoid
Arthritis Severity (CIRAS) is a numerical value that is
computed on the basis of orders for inflammatory mark-
ers, number of platelet counts and chemistry panels
ordered, rheumatoid factor, rehabilitation visits, age and
gender, presence of Felty’s syndrome, and number of
rheumatology visits. Details on the algorithm can be
found in Ting et al. [27]. The clinical characteristics also
included two administrative claims-based indices of gen-
eral health—the number of unique ICD-9-CM codes
recorded on claims in the baseline period and the number
of unique NDCs in the baseline period—that have been
shown to correlate with healthcare costs and adverse
outcomes such as emergency room visits and hospital-
izations [25].
Statistical Analyses
Bivariate analyses were used to display summary statistics
for the variable distributions, stratified by infused biologic
agent. Multivariable generalized estimating equations
(GEE) models—which accounted for the possibility of
multiple observations per patient—were used to compare
the healthcare cost outcomes between the infused biologic
agents, adjusting for patient demographics and clinical
characteristics listed in Tables 1 and 2 [28–30]. These
models used an independent covariance structure, log link,
and gamma distribution. Predicted adjusted incremental
costs and their associated 95 % confidence intervals were
obtained via least squares means calculated in the frame-
work of the GEE model relating costs to the covariates. All
analyses were performed using SAS version 9.2 (Cary, NC,
USA). P values \0.05 were considered, a priori, to be
statistically significant. P values are reported only for
Table 1 Patient demographics
ABA abatacept, CDHP
Consumer Directed Health Plan,
EPO Exclusive Provider
Organization, HDHP High
Deductible Health Plan, HMO
Health Maintenance
Organization, INF infliximab,




TCZ (N = 1,090) ABA (N = 1,759) INF (N = 922)
Age (mean ± SD) 54.7 ± 12.3 55.4 ± 12.8 53.5 ± 13.2
Female (%) 83.1 83.2 81.2
Geographic region (%)
Northeast 12.3 11.8 13.3
North Central 27.3 28.1 22.2
South 39.0 42.0 43.5
West 20.6 17.1 20.0
Unknown 0.7 1.0 1.0
Insurance plan type (%)
Comprehensive 11.0 13.8 12.4
EPO 1.7 1.9 1.3
HMO 15.2 14.1 16.7
POS 7.9 8.2 6.9
PPO 53.9 53.2 55.0
POS with capitation 0.9 0.9 0.8
CDHP 3.7 2.9 2.4
HDHP 1.7 1.8 1.6
Unknown 4.0 3.2 2.9
Population density (%)
Urban 84.9 85.2 83.8
Rural 14.4 13.8 15.2
Unknown 0.7 1.0 1.0
Year of index (%)
2010 33.4 48.9 47.7
2011 66.6 51.1 52.3
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multivariable-adjusted results, as these are the only ana-
lyses on which inferences were based.
Results
Patient Characteristics
Figure 1 displays the sample attrition associated with the
application of each study inclusion and exclusion criterion.
The final sample comprised 3,771 infused biologic
initiations.
Tables 1 and 2 display patients’ demographics and
baseline clinical characteristics, respectively, stratified by
infused biologic agent. The average patient age differed
little across the biologics, ranging from 53.5 years in
infliximab-treated patients to 55.4 years in abatacept-
treated patients. The proportion of females also differed
little across the biologics, ranging from 81.2 % in inflix-
imab-treated patients to 83.2 % in abatacept-treated
patients. The median follow-up ranged from 251 days
among tocilizumab-treated patients to 280 days among
abatacept-treated patients. Tocilizumab-treated patients
had the numerically greatest proportions of patients with
baseline use of corticosteroids, baseline use of analgesics,
and presence of extra-articular disease, and the numerically
greatest values of the number of unique 3-digit ICD-9-CM
diagnosis codes and number of unique NDCs, all of which
are indicative that tocilizumab-treated patients had poorer
baseline health status than abatacept- and infliximab-
treated patients.
Healthcare Cost Outcomes
Table 3 displays unadjusted PPPM biologic and RA-
related healthcare utilization and costs. The mean PPPM
[standard deviation (SD)] total RA-related healthcare costs
were $2,815 ($3,615) for tocilizumab-treated patients,
$2,936 ($2,038) for abatacept-treated patients, and $3,720
($3,713) for infliximab-treated patients. The majority of
RA-related healthcare costs were driven by the cost of the
biologic, accounting for 78.2 % of the RA-related health-
care costs among tocilizumab-treated patients, 88.4 %
among abatacept-treated patients, and 87.2 % among
infliximab-treated patients. The mean (SD) count of
biologic administrations was 1.0 (0.2) for tocilizumab-
Table 2 Patient baseline clinical characteristics
TCZ (N = 1,090) ABA (N = 1,759) INF (N = 922)
Median follow-up in days 251 280 269
CIRAS (mean ± SD) 3.6 ± 0.9 3.5 ± 1.0 3.6 ± 1.1
NSAIDs (%) 38.5 39.3 41.9
Corticosteroids (%) 80.8 78.6 76.7
Analgesics (%) 63.9 58.6 56.9
Non-biologic DMARDs (mean ± SD) 0.9 ± 0.7 0.9 ± 0.7 1.0 ± 0.7
Non-biologic DMARDs (%)*
Methotrexate 50.3 50.9 61.2
Hydroxychloroquine 13.3 16.4 16.6
Leflunomide 14.1 13.3 15.1
Minocycline 1.1 1.3 0.9
Sulfasalazine 5.0 6.6 6.4
Cyclosporine 0.2 0.2 0.3
Azathioprine 5.4 3.2 2.2
Gold sodium thiomalate 0.1 0.0 0.2
Extra-articular disease** (%) 5.5 4.5 3.4
DCI (mean ± SD) 1.4 ± 0.9 1.4 ± 0.9 1.4 ± 0.9
Number of unique 3-digit ICD-9-CM (mean ± SD) 21.7 ± 16.6 18.8 ± 14.4 18.7 ± 14.6
Number of unique NDCs (mean ± SD) 21.2 ± 15.7 17.8 ± 12.3 18.5 ± 13.6
Immediately prior drug = anti-TNF (%) 49.5 85.8 72.5
ABA abatacept, CIRAS Claims-based Index for Rheumatoid Arthritis Severity, DCI Deyo–Charlson Comorbidity Index, DMARD disease-
modifying antirheumatic drug, ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification, INF infliximab, NDC
National Drug Code, NSAID non-steroidal anti-inflammatory drug, SD standard deviation, TCZ tocilizumab, TNF tumor necrosis factor-a
* The overall number of non-biologic DMARDs was adjusted for in the models as opposed to the individual non-biologic DMARD indicators
** Rheumatoid nodules, Sjo¨gren’s syndrome, retinal vasculitis, other vasculitis, Felty’s syndrome, or rheumatoid lung
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treated patients, 1.2 (0.5) for abatacept-treated patients, and
1.0 (0.5) for infliximab-treated patients.
Table 4 displays unadjusted PPPM all-cause healthcare
utilization and costs. The mean PPPM (SD) total all-cause
healthcare costs were $3,667 ($4,044) for tocilizumab-
treated patients, $3,842 ($3,426) for abatacept-treated
patients, and $4,739 ($6,058) for infliximab-treated patients.
As with RA-related healthcare costs, the majority of all-
cause costs were driven by the cost of the biologic, which is
captured in the ‘other outpatient services’ category.
Figure 2 displays multivariable-adjusted PPPM biolog-
ic, RA-related, and all-cause healthcare costs. When
compared with abatacept-treated patients, tocilizumab-
treated patients had mean (95 % confidence interval)
multivariable-adjusted healthcare costs that were $703
(608–798) lower for biologic costs, $692 (550–834) lower
for RA-related costs, and $693 (485–900) lower for all-
cause costs (all P \ 0.05) (Table 5). When compared with
infliximab-treated patients, tocilizumab-treated patients
had mean (95 % confidence interval) multivariable-
adjusted healthcare costs that were $1,246 (1,074–1,418)
lower for biologic costs, $1,362 (1,123–1,601) lower for
RA-related costs, and $1,558 (1,153–1,964) lower for all-
cause costs (all P \ 0.05).
Discussion
To our knowledge, this study is the first to compare
healthcare costs between RA patients treated with infused
Fig. 1 Sample selection
attrition. RA rheumatoid
arthritis
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biologics after previously using at least one other biologic
agent. We found that among such patients, those treated
with tocilizumab had the lowest real-world healthcare
costs, largely driven by lower costs directly related to
biologic treatment.
Owing to the uniqueness of the present study’s data,
there are very few studies to which ours can be compared.
Wong et al. [20] used data from 72 US medical clinics to
examine the drug and administration costs for abatacept,
infliximab, and rituximab among RA patients initiating
treatment between January 1, 2006 and December 31,
2008. They reported that mean (SD) unadjusted total costs
per infusion visit were $1,827 ($622) for abatacept, $2,828
($1,282) for infliximab, and $6,076 ($1,689) for rituximab.
Though the reported trend of infliximab being more costly
than abatacept on a per-visit basis is consistent with the
present study’s findings on these two biologics, the study’s
cost comparisons were substantially confounded by the
differences in the frequency of administration of the stud-
ied agents, which were unaccounted for in the per-visit cost
comparisons. For example, abatacept is administered at 0,
2, and 4 weeks, and then every 4 weeks thereafter; inflix-
imab, is administered at 0, 2, and 6 weeks, and then every
4–8 weeks thereafter; and rituximab is administered as two
infusions separated by 2 weeks every 24 weeks or on the
basis of clinical evaluation, but not sooner than every
16 weeks [5–7]. Thus, the data from Wong et al. [20] are
difficult to interpret when trying to understand total drug
Table 3 Unadjusted per-patient
per-month biologic and RA-
related healthcare utilization
and costs
Healthcare costs were expressed
in 2011 constant US dollars
ABA abatacept, INF infliximab,








azathioprine, and gold sodium
thiomalate





TCZ (N = 1,090) ABA (N = 1,759) INF (N = 922)
Mean SD Mean SD Mean SD
Inpatient admissions
Count 0.0 ±0.1 0.0 ±0.1 0.0 ±0.1
Cost $282 ±$3,196 $106 ±$893 $211 ±$1,652
Emergency room visits
Count 0.0 ±0.1 0.0 ±0.1 0.0 ±0.1
Cost $6 ±$54 $5 ±$39 $4 ±$37
Outpatient office visits
Count 0.7 ±0.6 0.7 ±0.6 0.7 ±0.8
Cost $67 ±$88 $60 ±$69 $63 ±$69
Other outpatient services
Count 3.7 ±3.3 3.3 ±3.6 3.3 ±3.7
Cost $164 ±$446 $109 ±$317 $132 ±$1,047
Outpatient prescription claims
Count 2.5 ±1.2 2.7 ±1.3 2.6 ±1.7
Cost $2,295 ±$1,573 $2,657 ±$1,749 $3,309 ±$2,838
Biologic DMARDs
Count of biologic administrations 1.0 ±0.2 1.2 ±0.5 1.0 ±0.5
Cost of biologic drug $2,004 ±$1,469 $2,356 ±$1,693 $2,979 ±$2,727
Cost of biologic administration $197 ±$163 $240 ±$190 $266 ±$281
Total cost of biologic drug ? administration
Insurer-paid $2,105 ±$1,509 $2,469 ±$1,685 $3,107 ±$2,792
Patient-paid $97 ±$152 $127 ±$254 $138 ±$317
Total $2,202 ±$1,512 $2,596 ±$1,745 $3,244 ±$2,832
Non-biologic DMARDs*
Count 0.4 ±0.5 ±0.4 ±0.5 0.5 ±0.5
Cost $16 ±$39 ±$13 ±$29 $15 ±$28
Other RA Prescriptions**
Count 1.1 ±1.0 ±1.0 ±1.0 1.1 ±1.4
Cost $78 ±$301 ±$48 ±$124 $50 ±$165
Total RA-related healthcare resource utilization
Insurer-paid $2,668 ±$3,547 $2,771 ±$1,974 $3,542 ±$3,667
Patient-paid $147 ±$199 $165 ±$269 $178 ±$344
Total $2,815 ±$3,615 $2,936 ±$2,038 $3,720 ±$3,713
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and administration costs that would be expected while a
patient is being treated with infused agents.
In another prior study, Bonafede et al. [31] estimated
annual biologic treatment costs for subcutaneous and
infused biologics using a unit-cost approach, also finding
differences among the infused biologic agents abatacept,
infliximab, and rituximab. Results from the study were also
somewhat consistent with the present analyses in that they,
too, associated abatacept with lower average annual costs
than infliximab ($16,738 vs. $21,273, respectively). The
analyses were intended to be purely descriptive, however,
and made no attempts to adjust for inherent differences in
patient characteristics that may drive differences in
healthcare costs [21].
In one of the only other studies to report cost data for
tocilizumab, Liu et al. [21] performed an indirect analysis
of cost per responder in RA using clinical trial data and
published drug acquisition and administration costs for
FDA-approved RA biologics. They estimated that among
the infused therapies, tocilizumab had the numerically
lowest mean (95 % confidence interval) cost per responder
at $31,363 (14,713–64,232), compared with $50,496
(25,819–92,069) for infliximab and $61,088 (34,791–
104,295) for abatacept. Though these data are consistent
Table 4 Unadjusted per-patient
per-month all-cause healthcare
utilization and costs
Healthcare costs were expressed
in 2011 constant US dollars
ABA abatacept, INF infliximab,
SD standard deviation, TCZ
tocilizumab
TCZ (N = 1,090) ABA (N = 1,759) INF (N = 922)
Mean SD Mean SD Mean SD
Inpatient admissions
Count 0.0 ±0.1 0.0 ±0.1 0.0 ±0.1
Cost $415 ±$3,353 $316 ±$2,457 $505 ±$4,414
Emergency room visits
Count 0.1 ±0.2 0.1 ±0.2 0.1 ±0.2
Cost $33 ±$130 $41 ±$265 $42 ±$254
Outpatient office visits
Count 1.5 ±1.0 1.4 ±1.0 1.4 ±1.2
Cost $142 ±$150 $126 ±$109 $131 ±$114
Other outpatient services
Count 9.2 ±5.3 9.1 ±6.0 9.6 ±7.0
Cost $2,701 ±$1,762 $3,008 ±$1,923 $3,727 ±$3,927
Outpatient prescription claims
Count 4.3 ±3.2 4.0 ±3.1 4.1 ±3.2
Cost $376 ±$593 $350 ±$672 $334 ±$688
Total healthcare resource utilization
Insurer-paid $3,428 ±$3,959 $3,590 ±$3,345 $4,468 ±$6,009
Patient-paid $239 ±$237 $252 ±$306 $270 ±$375
Total $3,667 ±$4,044 $3,842 ±$3,426 $4,739 ±$6,058
Fig. 2 Multivariable-adjusted
(see Table 5) per-patient per-
month healthcare costs. ABA
abatacept, INF infliximab, RA
rheumatoid arthritis, TCZ
tocilizumab
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with the present study’s findings regarding tocilizumab, it
is important to consider that Liu et al.’s results were based
on a simulation as opposed to being based upon actual
observational data.
In the present study, the majority of all-cause costs were
accounted for by the biologic therapies, suggesting that the
real-world patterns of use of these therapies may be
amongst the most important cost drivers for RA patients.
The PPPM number of administrations for infliximab was
1.0; the expected number of administrations per month
would be closer to 0.5 if infliximab were administered
every 8 weeks as recommended for most patients on label.
Thus, even after accounting for the more frequent induction
doses (0, 2, 6 weeks), these higher than expected PPPM
administrations suggest that dose escalation in the form of
more frequent administration was occurring for infliximab.
This is consistent with prior analyses that have suggested
that dose escalation happens frequently in infliximab [11,
15, 17–19, 32]. While abatacept does not have a labeled
option for dose escalation, tocilizumab may be prescribed
at either 4 mg/kg every 4 weeks or 8 mg/kg every 4 weeks
on the basis of clinical response [5, 8].
In a post hoc exploratory analysis of tocilizumab-treated
patients, we attempted to estimate the proportion that dose
escalated from 4 mg/kg to 8 mg/kg on the basis of changes
in paid claim amounts. The Kaplan-Meier estimated
probability of dose escalation from 4 mg/kg to 8 mg/kg
within 1 year after initiation of tocilizumab was
approximately 75 %. Given the relatively short follow-up
of the present study (median ranging from 251 days in
infliximab-treated patients to 280 days in abatacept-treated
patients), further research should look at longer-term cost
comparisons, which may be different from those reported
in the present study, depending on the dosing patterns for
each drug.
This study was subject to limitations. Procedure and
diagnosis coding on administrative claims data are recorded
by healthcare practitioners to support reimbursement.
Measurement error can result from miscoded or non-coded
administrative claims. For example, claims related to RA
may not have been coded with an RA diagnosis code,
thereby potentially underestimating the costs of RA. Though
this study used multivariable analyses to adjust for differ-
ences in measurable patient characteristics between the in-
fused biologics, we cannot rule out the possibility of residual
confounding. Because of data limitations, we were unable to
discern the exact line of therapy each patient was receiving.
Compared with patients who are in earlier lines of biologic
therapy, patients who have previously failed several
biologics may be more refractory and may have higher
RA-related costs, all-cause costs, and higher biologic-
related costs in part due to more dose escalation [32]. This
study only compared the healthcare costs from a US payer
perspective and did not compare the clinical effectiveness of
the different treatments. Administrative claims data do not
provide information on clinical outcomes such as tender/
swollen joint counts, pain, and physical function (among
others). Thus, we could not assess the comparative clinical
effectiveness of these therapies. Furthermore, the database
does not have information on weight, which affects the total
dose given to patients. However, using persistence on
therapy as a proxy for effectiveness, our previous research
has shown that tocilizumab patients had better persistence
than patients receiving infliximab and abatacept [33].
Finally these results are not generalizable to the entire US
RA population, including those who are uninsured or
insured through Medicaid.
Conclusion
Among RA patients treated with infused biologics after
previously using at least one other biologic, patients treated
with tocilizumab had the lowest real-world healthcare
costs, largely driven by lower costs directly related to
biologic treatment. Such biologic-related cost differences
may be driven by variations in real-world treatment pat-
terns (e.g., dose, treatment frequency, dose escalation).
Table 5 Multivariable-adjusted per-patient per-month cost differences
Multivariable-adjusted* mean (95 % confidence interval) per-patient per-month cost difference**
ABA minus TCZ INF minus TCZ
Biologic costs $703 (608–798) $1,246 (1,074–1,418)
RA-related healthcare costs $692 (550–834) $1,362 (1,123–1,601)
All-cause healthcare costs $693 (485–900) $1,558 (1,153–1,964)
ABA abatacept, INF infliximab, RA rheumatoid arthritis, TCZ tocilizumab
* The multivariable models adjusted all variables listed in Tables 1 and 2 (median follow-up excepted); adjusted costs are based on predictions
set at the cohort-level mean values of continuous covariates and the base values of categorical covariates
** All cost differences were statistically significant at P \ 0.05
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